Rochester, New York: Dupixent Lawsuits

Jed Dietrich, Esq., Recognized as a Super Lawyer and American Institute of Trial Lawyers Litigator of the Year, is Committed to Defending the Rights of Rochester Families. If You or Your Child Has Been Diagnosed with CTCL After Taking Dupixent, You Deserve Aggressive Representation and an Experienced Personal Injury Lawyer Willing to Fight for Your Rights.

Dupixent is a drug that is most frequently used to treat conditions like asthma and eczema.

Unlike topical ointments, the kinds of creams and lotions you would apply directly to the skin, medications like Dupixent work from the inside out. By targeting and blocking certain protein receptors, Dupixent relieves chronic inflammation that would not respond to other treatments. For patients with eczema, reduced inflammation can eradicate rashes and reduce itchiness. It can also help people with asthma by relieving swelling in and around the airway.

However, Dupixent is not perfect, and scientists now believe that this drug could cause or worsen cutaneous T-cell lymphoma, a rare type of blood cancer that is notoriously difficult to diagnose.

You should not have to pay the price for a multibillion-dollar pharmaceutical company’s oversight. Although a personal injury lawsuit cannot undo a life-altering diagnosis, a settlement or court-ordered award could help you secure the resources you need to keep fighting and, eventually, begin rebuilding your life. Of course, filing a lawsuit is much easier than winning one. Fortunately, you may not have to do it alone.

Since our founding in 2005, the Dietrich Law Firm P.C. has helped our clients assert their rights to a fair recovery. A recognized U.S. News & World Report Best Law Firm, we know what it takes to build an ironclad, evidence-based case for compensation, and we have the results to prove it.

Call Jed Dietrich, Esq., today at 585-939-3939 to speak to a Dupixent injury lawyer near Rochester and schedule your 100% free, no-obligation consultation as soon as possible.

Medical scientists believe that people who take Dupixent could be at risk for cutaneous T-cell lymphoma, often abbreviated as “CTCL.” Cutaneous T-cell lymphoma starts in your white blood cells, but it can spread to other parts of the body, too. More specifically, CTCL develops in white blood cells called T cells, which fight germs and bacteria.

Cutaneous T-cell lymphoma has several subtypes. These two are the most common:

1. Mycosis fungoides. Mycosis fungoides is a slow-moving cancer. It is usually limited to the skin.
2. Sezary syndrome. Sezary syndrome is a less common form of CTCL. Unlike mycosis fungoides, it spreads quickly and can affect both the skin and the blood.

All cancers, including CTCL and its subtypes, are caused by genetic mutation.

Genetic mutations are anything but uncommon they are an ordinary, standard part of the biological process. However, some mutations can force cells to act in abnormal ways. If a mutation makes your white blood cells reproduce rapidly and uncontrollably, they could end up attacking the body and, over time, merge into tumors.

In the case of cutaneous T-cell lymphoma, mutated white cells will typically attack the skin. This can cause symptoms including, but not limited to, the following:

1. Patches of raised and scaly skin, which may or may not itch;
2. Patches of skin that turn red, pink, brown, or grey;
3. Patches of skin that are noticeably lighter than the skin around them;
4. Lumps and bumps that form on the skin before breaking open;
5. Enlarged or swollen lymph nodes;
6. Unexplained hair loss;
7. Thickened skin on your palms or the soles of your feet; and
8. A full-body rash that is scaly and itchy.

Most people who are diagnosed with CTCL do not develop all of these symptoms.

In fact, some subtypes of cutaneous T-cell lymphoma, especially mycosis fungoides, often manifest as little more than isolated patches of scaly, itchy skin. This can make obtaining an accurate diagnosis difficult. Even doctors sometimes miss the tell-tale signs of CTCL and may inadvertently attempt to treat cutaneous T-cell lymphoma as eczema, dermatitis, or another non-cancerous skin condition.

A growing body of evidence strongly suggests that there is a relationship between Dupixent and cutaneous T-cell lymphoma. In one study, scientists noted that “reports have linked [Dupixent] with exacerbating symptoms and accelerated disease progression of cutaneous T-cell lymphoma.” Another report posited an “increased risk of CTCL … in the cohort of [acute dermatitis] patients who used” Dupixent.

Researchers have effectively established a potential link between Dupixent and cancer, but nobody understands how this medication could cause or exacerbate CTCL. Some of the proposed explanations include, but are not limited to, the following:

1. Masking early-warning signs. Dupixent treats inflammation, rashes, and other skin abnormalities. These symptoms are characteristic of eczema and other types of atopic dermatitis, but they are also the early-warning signs of cutaneous T-cell lymphoma. Taking Dupixent could therefore suppress CTCL symptoms, thereby delaying both diagnosis and treatment.
2. Revealing cancer in its initial stages. Some people who take Dupixent for eczema are later diagnosed with cutaneous T-cell lymphoma. Taking Dupixent can worsen some CTCL symptoms and, potentially, trigger painful lesions. This has several implications. It could mean that Dupixent can “unmask” hidden cancer; it could also mean that Dupixent accelerates or worsens undiagnosed cancers.
3. Disrupting immune system functions. Dupixent works by targeting protein receptors and blocking immune system pathways. Some scientists have speculated that this could make it more difficult for the body to monitor overall immune system efficacy, making it easier for cells to mutate and become cancerous.
4. Accelerating the progression of cancer. Most people who take Dupixent and develop cancer are diagnosed within a year of starting their prescription.

Scientists may not understand the nature of the relationship between Dupixent and CTCL, but that does not mean you cannot take action. Under state and federal law, pharmaceutical companies have a responsibility to warn patients of potential side effects and complications. If and when a manufacturer abrogates this responsibility, they could be held liable for the cost of any resulting injury.

You could be entitled to file a Dupixent cancer lawsuit if you meet the following conditions:

1. You were prescribed Dupixent for eczema, asthma, or another approved use;
2. You were diagnosed with cutaneous T-cell lymphoma after taking Dupixent; and
3. You were not diagnosed with a condition like Hodgkin’s lymphoma, non-Hodgkin lymphoma, or leukemia before starting Dupixent.

For more than 30 years, the Dietrich Law Firm P.C. has fought to protect the rights of Rochester families, helping our clients secure more than $300 million in damages money that they have used to eliminate existing debt, seek the best-quality care, and begin rebuilding after receiving a life-altering diagnosis. We could help you, too. Please send us a message online or call us today at 585-939-3939 to speak to a Dupixent cancer lawyer near Rochester and schedule your 100% free, no-obligation consultation as soon as possible.

Call the Dietrich Law Firm P.C. immediately at 585-939-3939 so that our aggressive, tenacious, and hardworking personal injury lawyers can fight to obtain the best result for your personal injury claim in Rochester, New York. We are available 24 hours a day, 7 days a week, and there is never a fee until we WIN for you!